

**BRIAN** We have many clinical trials that are ongoing at North Shore. These include genetic trials such as the IMPACT.

**HELFAND:**

The IMPACT is a study that is originated in the UK that is really designed to assess whether BRCA1 and 2 and now ATM mutation carriers have not only increased risk of prostate cancer, but aggressive disease, and assess the impact of earlier screening on these patients. The early results of this study do suggest that there's a benefit to prostate cancer screening at earlier time points.

We also have many other studies that are in collaboration with different pharma industries as well as our own homegrown studies that are really designed to enhance the prostate cancer experience, assess the underlying tumor biology, assess patient experience through prostate cancer screening through treatment, assess anxiety, and even assess how different behavioral modifications can impact their outcomes.